Baylor College of Medicine has synthesized activin receptor type-1 (ACVR1; ALK2; ACTR-I) and/or serine/threonine-protein kinase receptor R3 (ACVRL1; ALK1) inhibitors reported to be useful for the treatment of cancer, fibrodysplasia ossificans progressiva (FOP), atherosclerosis and iron deficiency anemia.

Researchers have developed and tested a taurultam-derived oxathiazine compound, GP-2250, for the potential treatment of ovarian cancer. Taurolidine, a substance derived from the amino acid taurine, has been shown to have antiproliferative and antineoplastic activity in vitro and in vivo against various cancer types. GP-2250 was tested in vitro in several ovarian cancer cell lines, as well as in vivo as a monotherapy and in combination with standard-of-care drugs and PARP inhibitors.

Hainan Simcere Pharmaceutical Co. Ltd. has patented E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.

Yarrow Therapeutics Inc. has divulged antibody-drug conjugates comprising antibody or antigen binding fragments covalently linked to ecteinascidin derivatives through linkers reported to be useful for the treatment of cancer.

Chengdu Chipscreen Pharmaceutical Ltd. has discovered Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

China’s Genor Biopharma Co. Ltd. agreed to out-license GB-261, its bispecific antibody candidate primarily targeting B-cell lymphomas, to TRC 2004 Inc., a U.S.-based newco co-founded by Third Rock Ventures LLC and Two River Group Holdings LLC.

Researchers at the University of Bradford have prepared and tested duocarmycins reported to be useful for the treatment of cancer.

Otsuka Pharmaceutical Co. Ltd. has disclosed antibody-drug conjugates comprising humanized monoclonal antibody targeting syndecan-1 (SDC1; SYND1; CD138) covalently linked to anticancer and/or cytotoxic agents through linkers reported to be useful for the treatment of cancer.